Regulatory & Policy

Polaryx Therapeutics Secures FDA Fast Track Designation for PLX-200 Targeting Rare CLN2 Disease

Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company headquartered in Paramus, New Jersey, announced that the U.S. Food and...

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 in CLN2 Disease

Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company headquartered in Paramus, New Jersey, announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PLX-200, an oral small molecule peroxisome proliferator-activated receptor alpha (PPARα) agonist comprised of gemfibrozil, for the treatment of Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease). The PLX-200 Fast Track designation enables more frequent FDA interactions and eligibility for rolling review of a future marketing application. PLX-200 has also received Rare Pediatric Disease Designation for CLN2 disease and Orphan Drug Designation for Neuronal Ceroid Lipofuscinosis from the FDA.

PLX-200 is being advanced through SOTERIA, a Phase II, open-label, single-arm basket trial designed to evaluate safety, tolerability, and clinical activity across four lysosomal storage disorders: CLN2, CLN3, Krabbe disease, and Sandhoff disease. Polaryx received a safe-to-proceed letter from the FDA in October 2025 and plans to initiate SOTERIA in Q3 2026 at sites in the United States, Europe, and Asia. For the CLN2 and CLN3 cohorts, the trial will incorporate analyses comparing treated patients against natural history data as a control arm. No NCT identifier for SOTERIA was disclosed in the company's announcement. Gemfibrozil itself holds longstanding FDA approval as a lipid-regulating agent for adults with hypertriglyceridemia, marketed as Lopid since 1981, but has not previously been approved for pediatric or neurological indications.

Research context

CLN2 disease is a rare, autosomal recessive neurodegenerative disorder caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1. Onset typically occurs between ages two and four, with rapid progression of seizures, language loss, motor decline, and vision impairment, leading to death in adolescence. The only approved disease-modifying therapy is cerliponase alfa (Brineura), a recombinant enzyme replacement therapy administered via intracerebroventricular infusion every two weeks. While cerliponase alfa has been shown to slow functional decline and improve survival, it does not halt disease progression and requires invasive delivery through a surgically implanted reservoir. Delayed diagnosis remains a documented barrier to treatment effectiveness, as neurodegeneration is already advanced by the time many patients begin therapy.

The AllSci BriefSystematic R&D and deal news. Daily.

PLX-200 differs from cerliponase alfa in both modality and route of administration. Where cerliponase alfa delivers recombinant enzyme directly into the central nervous system through biweekly intracerebroventricular infusions, PLX-200 is an oral small molecule whose active ingredient, gemfibrozil, has documented ability to cross the blood-brain barrier in preclinical studies. Rather than replacing a single deficient enzyme, PLX-200 acts as a PPARα agonist with a mechanism that Polaryx states addresses lysosomal dysfunction, neuroinflammation, and neuronal loss across multiple lysosomal storage disorders. This broader mechanism underlies the basket trial design of SOTERIA, which enrolls patients with four distinct conditions. The oral route could reduce the procedural burden associated with current CLN2 disease treatment, though no clinical efficacy data for PLX-200 in any lysosomal storage disorder have been reported to date.

The evidence base supporting the Fast Track Designation was not detailed in the company's announcement. Polaryx has cited validated animal models that mimic human clinical phenotypes, but no specific preclinical datasets, endpoints, or effect sizes were disclosed. The company has indicated that, should SOTERIA data demonstrate clinical activity, it may seek conditional marketing authorization. The absence of published clinical data for PLX-200 in CLN2 or related disorders represents a gap that the Phase II trial is intended to address.


Spot something wrong? Report an issue with this article